For example,
New blood test offers breakthrough:
Dana-Farber Cancer Institute researchers have developed a blood test that could transform the diagnosis. Consequently, monitoring of multiple myeloma (MM) and its precursor conditions. In addition, The new method. Moreover, known as SWIFT-SEQ, uses a unique sequencing for profile for profile circulating tumor cells (CTC) in the blood, offering a non-invasive alternative to traditional biopsies of bone marrow.
The study was published in Nature cancer.
“A lot of work has been devoted to the identification of genomic. Moreover, transcriptomic characteristics which predict more worse results in mm, but we still do not have tests to measure them in our patients,” said the main author, Dr. However, Irene M. Similarly, Ghobrial. In addition, As a clinician, this is the type of new generation test that I would like to order for my new blood test offers breakthrough patients. Consequently, “”
Multiple myeloma is difficult bone marrow cancer. Furthermore, often preceded by conditions such as monoclonal gammopathy of indefinite meaning (MGU) and the multiple myelome that broods (SMM). Traditionally, bone marrow biopsies have been used to assess risks and monitor genetic changes under these conditions. However. these biopsies are painful, infrequent and the support technique, in situ hybridization by fluorescence (FISH), often does not reach clear results, leading to a less effective risk assessment and to influence treatment decisions.
“It would be incredible if we had a blood test that can surpass fish. operate in the majority of patients-we believe that Swift-Seq may well be this test,” said Dr. Romanos Sklavenitis-Pistofidis, co-author.
SWIFT-SEQ offers an innovative alternative by allowing doctors to carry out risk assessments. genetic surveillance using a simple blood test, which makes the process much easier and more reliable. Beyond CTC counting, SWIFT-SEQ new blood test offers breakthrough provides a detailed genetic profile, identifying crucial key genetic changes to understand the disease. This method goes beyond the precision of bone marrow tests like fish. In addition. SWIFT-SEQ assesses tumor growth rates and identifies important gene models that can predict patient results, all from a single blood sample.
“SWIFT-SEQ is a powerful option because it can measure the number of CTCs. to characterize the genomic alterations of the tumor, to estimate the proliferation capacity of the tumor and to measure the signatures of generately useful genes in a single test and from a blood sample,” said Ghobrial.
The study involved 101 healthy patients. donors, demonstrating that Swift-Seq managed to capture CTC in 90% of patients with MGU, SMM and MM. He notably identified CTC in 95% of SMM patients. 94% of patients with newly diagnosed MM, the groups most likely to benefit from an improvement in risk stratification new blood test offers breakthrough and genomic monitoring. SWIFT-SEQ’s ability to list CTCs as a function of the molecular barcode of the tumor. rather than relying on cellular surface markers, distinguishes it from existing methods such as flow cytometry.
SWIFT-SEQ not only measures several clinically relevant characteristics directly from a blood sample. but also provides new information on the biology of the circulation of tumor cells.
We have identified a genetic signature which. in our view, captures the circulatory capacity of the tumor and can partly explain some of the unexplained mysteries of the biology of myelome. This can have a huge impact on how we think about reducing the spread of tumors in patients with myeloma. could lead to the development of new drugs for patients. “”
Dr Elizabeth D. Lightbody. co-prime auteur
The introduction of SWIFT-SEQ marks a significant progression in the diagnosis of myelome, offering a new blood test offers breakthrough mini-invasive method to obtain several clinically useful layers of information from a single blood test. This breakthrough could lead to better results for patients and a more in -depth understanding of the biology of myeloma.
New blood test offers breakthrough
Further reading: Make aquagym, the solution against chronic back pain? – A partnership to facilitate access to care in the municipalities of Espace Sud en Martinique – These unknown signs not to ignore aufeminin.com – Australian scientists discover a new way of stopping aggressive cancer growth – Genetic therapy restores hearing in deaf patients in a few weeks after a single injection!.
